Cell Culture – News and Features

AppTec to manufacture multiple sclerosis drug candidate for toxicology studies and clinical trial using ACE System.

Preclinical data for oncogenic B-Raf inhibitor presented at American Association for Cancer Research Annual Meeting.

A unique public-private partnership led by researchers at the Broad Institute of MIT and Harvard creates RNAi-based inhibitors for nearly every human and mouse gene.

Cancer Cell paper validates use of Anti-S1P antibody as a potential therapeutic.

Dr Chris Mann has been invited to speak at the 10th Cell Culture Engineering Conference.

This partnership highlights the interest in visual-based screening technologies to identify selective drug candidates.

Trellis Bioscience will provide its Antibody CellSpot™ technology to PDL BioPharma.

The collection now carries 65,000 shRNA vector constructs that target 9,500 human genes and 3,400 mouse genes.

Gene’s importance in cancers of the lung and head and neck may make it a viable drug target.

The study opens an avenue to develop therapeutic drugs to target the epidermal growth factor receptor genes.